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Abstract
Excessive post-operative wound healing with subsequent scarring frequently leads to surgical failure of glaucoma filtration surgery (trabeculec-
tomy). We investigated the hypothesis that placental growth factor (PlGF) plays a role in post-operative scar formation, and that it therefore
may be a target for improvement of filtration surgery outcome. ELISA experiments showed that PlGF levels were significantly increased in aque-
ous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound heal-
ing after trabeculectomy. Using a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously
characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area. This
was associated with a significant reduction in post-operative proliferation, inflammation and angiogenesis during the first post-operative days
after surgery, and with a decrease in collagen deposition at later stages. Furthermore, inhibition of PlGF seemed to be more effective than anti-
VEGF-R2 treatment in improving surgical outcome, possibly via its additional effect on inflammation. These results render PlGF an appealing
target for ocular wound healing and point to potential therapeutic benefits of PlGF inhibition for the prevention of surgical failure.
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Introduction
Trabeculectomy is a widespread, well-studied surgical method of
intraocular pressure (IOP) reduction in the management of glaucoma
[1, 2]. Subconjunctival fibrosis and wound healing form the major
reasons for insufficient aqueous filtration and surgical failure [3].
The process of wound healing is a cascade of different processes
that are closely linked, including coagulative and inflammatory
phases, followed by proliferation and repair phases and finally, the
remodelling phase [4]. Various growth factors are known to be
involved in post-operative wound healing, e.g. transforming growth
factor (TGF)-b, fibroblast growth factor (FGF) and VEGF [5–7].
Importantly, a recent study of Rodriguez-Agirretxe et al. showed that
up-regulation of TGF-b and VEGF in conjunctival biopsies of glau-
coma patients was highly correlated with surgical failure, whereas
up-regulation of other factors [e.g. interleukin (IL)-6, IL-8, matrix
metalloproteinase (MMP)-1, MMP-2, etc.] were associated with sur-
gical success [8]. VEGF plays an important role in both physiological
[9] and pathological angiogenesis [10, 11]. VEGF-R2 mediates most
biologically relevant VEGF responses, including vascular permeabil-
ity, cell migration and proliferation [12]. Alternative splicing of a sin-
gle VEGF gene can result in multiple isoforms, such as VEGF121,
VEGF165 and VEGF189 [13]. We have previously shown that pharma-
cological enhancement of trabeculectomy using VEGF inhibitors was
able to significantly improve rates of surgical success. A single
injection of bevacizumab (non-selective VEGF inhibitor) at the time
of trabeculectomy could improve the surgical outcome by reducing
post-operative angiogenesis during the initial phase, and collagen
deposition at later stages in a rabbit trabeculectomy model [14].
Injection(s) of pegaptanib (a selective VEGF165 inhibitor) improved
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surgical outcome less efficiently by reducing angiogenesis only,
because of a retained action of VEGF121 and VEGF189, which have a
more pronounced effect on fibrosis [15]. Importantly, neither selec-
tive nor non-selective VEGF inhibition could reduce inflammation, an
important process in post-operative wound healing. Importantly, in
different animal models of wound healing, it has also been described
that administration of bevacizumab does not reduce inflammation
[16–19]. This can presumably be partially explained by an up-regula-
tion of placental growth factor (PlGF), a pro-inflammatory growth
factor [20–22]. PlGF, a VEGF-homologue, which solely binds to
VEGF-R1 [23], only acts on pathological angiogenesis [24] and
inflammation [25] and is not involved in physiological angiogenic
processes. A monoclonal anti-PlGF antibody against mouse PlGF
(5D11D4), developed by ThromboGenics NV (Heverlee, Belgium),
was previously shown to inhibit tumour growth in different mouse
tumour models [26–28]. Moreover, Van de Veire et al. showed a
dose-dependent reduction in murine choroidal neovascularization
(CNV) formation, by reducing angiogenesis and inflammation. They
also demonstrated that intraocular use of the antibody was safe
[28]. Other studies showed a beneficial effect of the PlGF antibody
in the development of atherosclerotic plaque formation [29] and liver
cirrhosis [30], by its inhibitory effects on inflammation and fibrosis.
In this study, the potential therapeutic effect of a monoclonal PlGF
antibody and its mechanism of action in the inhibition of wound heal-
ing after glaucoma filtration surgery were evaluated and compared
with the effects of an antibody to VEGF-R2. Our findings suggest that
inhibition of PlGF might be more effective in improving surgical out-
come as compared with VEGF-R2 inhibition, through its additional
effect on inflammation.
Materials and methods
All procedures conformed to the tenets of the Declaration of Helsinki
and written informed consent was obtained from patients after gaining
approval from the institutional human ethics committee (Institutional
Review Board of the University Hospitals Leuven). All animals were
used in accordance with the standards in the Association for Research
in Vision and Ophthalmology Statement for the Use of Animals in Oph-
thalmic and Vision Research. The Institutional Animal Care and
Research Advisory Committee of KU Leuven approved all experimental
animal procedures.
Patients and biochemical measurements
Samples of human aqueous humour (AH) and plasma were collected
from patients (n = 10) who underwent trabeculectomy for primary open
angle glaucoma (POAG) or phacoemulsification for senile cataract with-
out glaucoma (the control group). Glaucoma was defined as having
characteristic optic disc damage (based on cup/disc ratio, thinning of
neuroretinal rim, notching, disc haemorrhages, etc.) and visual field
defects. For the diagnosis of POAG, an untreated IOP of >21 mmHg
was required [31]. The surgeon collected samples of AH (100–200 ll)
immediately after limbal paracentesis to avoid the influence of intraocu-
lar trauma/surgery. Blood was collected in ethylene diamine tetracetic
acid (EDTA)-coated tubes and centrifuged for 15 min. at 1248 9 g AH
and plasma samples were stored immediately at 80°C until analysis.
PlGF protein levels were analysed in AH and plasma samples by using a
double-antibody ‘sandwich’ ELISA (R&D Systems, Minneapolis, MN,
USA), with a detection limit of 15.6 pg/ml. Concentrations were
expressed as pg/ml.
Cell culture and proliferation assay
Murine Tenon’s tissues were obtained from C57BL/6J mice before filtra-
tion surgery by dissecting a piece of the Tenon’s capsule. Murine Tenon
fibroblasts (MTF) were prepared by dissociating these freshly dissected
tissues mechanically and enzymatically. Tissue pieces were cut, trypsi-
nized for 30 min. and centrifuged at 312 9 g for 5 min. Primary Tenon
fibroblasts were propagated in DMEM medium (Invitrogen Corporation,
Carlsbad, CA, USA), supplemented with 10% foetal bovine serum (FBS;
Thermo Fisher Scientific, Rochester, NY, USA), 2 nM L-glutamate,
100 U/ml penicillin, 100 lg/ml streptomycin (all from Invitrogen). Sub-
confluent MTF were trypsinized and were seeded in 96-well plates at an
initial density of 5 9 103 cells/well in 100 ll complete medium. In one
series of experiments, the cells were serum starved (medium supple-
mented with 0.1% FBS) overnight, 6 hrs after cell seeding. The medium
of MTF was changed to fresh serum-free medium containing recombi-
nant murine PlGF and VEGF-A (further referred to as VEGF; 10, 25, 50
and 100 ng/ml; both from R&D Systems). In another series of experi-
ments, the complete medium of MTF was replaced by complete med-
ium, pre-incubated with PlGF and VEGF (50 ng/ml; R&D Systems) in
presence of anti-PlGF antibody (5D11D4), anti-VEGF-R2 antibody
(DC101) or an irrelevant mouse antibody (1C8) (0.1, 1, 10 and 100 lg/
ml). Forty-eight hours after growth factor or antibody administration,
cell proliferation was assessed in all experiments by using the WST-1
Cell Proliferation Assay System (Roche Diagnostics, Mannheim, Ger-
many). Complete or serum-free medium was used as controls.
Quantitative real time RT-PCR
RNA from MTF was isolated by using the RNeasy Minikit (Qiagen, Valencia,
CA, USA) and quantitative RT-PCR was performed, as described previously
[24]. Expression was normalized to that of the housekeeping gene b-actin.
Following forward (for) and reverse (rev) primers and probes (pro) labelled
with a fluorescent dye (FAM) and quencher (TAMRA) were used. Murine
b-actin: for 5′-AGA-GGG-AAA-TCG-TGC-GTG-AC-3′; rev 5′-CAA-TAG-TGA-
TGA-CCT-GGC-CGT-3′; pro 5′-CAC-TGC-CGC-ATC-CTC-TTC-CTC-CC-3′.
Murine PlGF: for 5′-CCC-TGT-CTG-CTG-GGA-ACA-AC-3′; rev 5′-CAG-TAG-
CTG-CGA-CCC-CAC-A-3′; pro 5′-ACA-GAA-GTG-GAA-GTG-GTG-CCT-TTC-
AAC-3′. Murine VEGF: for 5′-TGC-ACC-CAC-GAC-AGA-AGG-A-3′; rev 5′-
GGC-AGT-AGC-TTC-GCT-GGT-AGA-C-3′; pro 5′-CAG-AAG-TCC-CAT-GAA-
GTG-ATC-AAG-TTC-ATG-GA-3′. Murine VEGF-R1: for 5′-AGC-CCC-TCA-
CCA-TGG-AAG-A-3′; rev 5′-CCG-ATG-AAT-GCA-CTT-TCT-GGA-3′; pro 5′-
TTT-CCT-ACA-GTT-TCC-AAG-TGG-CCA-GAG-GC-3′. Murine VEGF-R2: for
5′-CCT-CTA-CAC-CTG-CCA-GGC-C-3′; rev 5′-TTC-CTG-GGC-ACC-TTC-T AT-
TAT-GAA-3′; pro 5′-TTG-GCT-GTG-CAA-GAG-CGG-AGA-CG-3′.
Rabbit model for glaucoma surgery
New Zealand rabbits (n = 5; 12–14 weeks old) were obtained from the
animal facility of KU Leuven. General anaesthesia was induced by intra-
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muscular injection of 50 mg/ml ketamin (Ketalar, Pfizer, Ann Arbor, MI,
USA) and 2% sedative (Rompun, Bayer Health Care, Pittsburgh, PA,
USA). Filtration surgery was performed on both eyes by using a tech-
nique as previously described [14]. Immediately after surgery, one eye
was injected with 25 mg/ml bevacizumab and the other eye was used
as a control and received an injection of 0.9% NaCl. For each eye,
200 ll was injected into the anterior chamber and 100 ll was injected
subconjunctivally into the filtration bleb, based on our previous study
[14]. Samples of AH and blood were obtained from the rabbits the day
before and on days 3, 7, 14 and 30 after surgery. Blood was collected
in EDTA-coated tubes and centrifuged for 15 min. at 1248 9 g AH and
plasma samples were stored immediately at 80°C until analysis. The
levels of PlGF protein were analysed with a quantitative sandwich
enzyme immunoassay technique with a detection limit of 1.0 pg/ml
(E04P0018; BlueGene, Shanghai, China). Plasma of a pregnant rabbit on
day 25 was used as a positive control, since we showed that it contains
high PlGF levels. Concentrations were expressed as pg/ml.
Mouse model of glaucoma filtration surgery
C57BL/6J mice (8–10 weeks old, Charles River Laboratories, Lyon,
France) were anaesthetized with an intaperitoneal injection of 10 times-
diluted (60 mg/kg final dose) sodium pentobarbital (Nembutal, 60 mg/
ml; CEVA Sante Animale, Brussels, Belgium). Before surgery, IOP was
measured in both eyes with a tonometer (TonoLab; Technop, Espoo,
Finland); 15 recordings per eye were averaged. Filtering surgery was
performed on both eyes by using a technique that has been described
previously and that results in a filtering bleb [32, 33]. Immediately after
surgery, mice were divided into different groups and their eyes were
injected with either 5D11D4 or DC101; an isotype-matched control anti-
body (1C8) was used as a negative control. The injections were per-
formed by using an analytic science syringe (SGE Analytic Science) and
glass capillaries with a diameter of 50–70 lm at the end, controlled by
the UMP3I Microsyringe Injector and Micro4 Controller (all from World
Precision Instruments Inc., Hertfordshire, UK).
In the first experiment (n = 10 eyes for all groups), mice were divided
into different groups to investigate the most optimal administration route
of the PlGF antibody. Immediately after surgery, the PlGF inhibitor
(5.2 lg) was intracamerally (AC) injected in the first group of mice, sub-
conjunctivally (SC) in the second group and the third group received an
intravitreal (IV) injection of 5D11D4. The isotype-matched control anti-
body (1C8) was used in every group as a negative control. In the second
experiment (n = 20 eyes for all groups), 5D11D4 (5.2 lg) was adminis-
tered in the first group of mice and a second group received DC101 injec-
tions (6.2 lg) as positive control. The third group of mice was treated
with 1C8 (4.8 lg) and was used as a negative control. For each eye, 1 ll
was injected into the AC. In a third experiment (n = 10 eyes for all
groups), repeated intracameral injections of antibodies (1 ll) were given
in the same concentration on days 0, 4 and 10. These concentrations
and time-points were based on previous intravitreal injections of the anti-
PlGF antibody performed by Van de Veire et al. [28]. Mice were clinically
examined on day 1 after surgery and then every 2 days until they were
killed. The IOP and bleb area were analysed under topical anaesthesia.
Commercial software (KS300; Zeiss, Oberkochen, Germany) was used to
determine the bleb size on bleb images of mice. These pictures were
taken with a digital camera (Canon PowerShot S50) by using a 39
optical zoom lens at a magnification of 49. Bleb survival was taken as
the end point of the study, while bleb failure was defined as the appear-
ance of a scarred and flat bleb at two consecutive measurements.
Histology, immunohistochemistry and
immunofluorescent stainings
Primary Tenon fibroblasts were identified based on their morphology, on
their immunopositivity after immunostaining for the mesenchymal cell
marker vimentin and on the absence of staining for the epithelial cell mar-
ker cytokeratin. Briefly, the cells were plated in a 12-well plate (10 9 104
cells per well) on a cover slip and were grown overnight. The next day,
the cells were fixed with 4% paraformaldehyde (PFA) for 30 min. at room
temperature (RT), permeabilized, and blocked with PBS - 0.1% Triton X-
100 - 0.3% BSA and 5% rabbit serum for 1 hr. Subsequently, the cells
were incubated overnight at 4°C with the primary antibodies. Murine anti-
bodies against vimentin (1/100; Sigma-Aldrich, V5255) and cytokeratin
(1/200; SC81714) and goat antibodies against murine VEGF (1/50;
SC1836) and PlGF (1/50; SC1882) were used (all from Santa Cruz Bio-
technology Inc). Immunofluorescent labelling was visualized after incuba-
tion for 1 hr at RT with appropriate secondary antibodies conjugated to
Alexa Fluor-568 and Alexa Fluor-488 (1/200; Invitrogen). Finally, the
cover slips were mounted with Prolong Gold with 4′,6-diamidino-
2-phenylindole (DAPI; Molecular Probes, Eugene, OR, USA). To confirm
the specificity of the primary antibodies, staining of cells incubated with-
out primary antibody was used as negative control. As a positive control
for the cytokeratin staining, murine melanoma B16/F10 cells (provided by
ThromboGenics, Heverlee, Belgium) were used [34].
On post-operative days 8 and 14 after surgery, mice were killed by
cervical dislocation. Both eyes were enucleated and whole eyes were
fixed in 1% PFA overnight. Serial paraffin sections were cut at 7 lm
thickness in five series of five glass slides. Haematoxylin and eosin stain-
ing was performed on the first slide from each series to localize the bleb
(positive area of analysis) and the rest of the eye (negative area of analy-
sis). Proliferation was checked by performing a Ki67 staining. The slides
were incubated overnight with a goat anti-murine Ki67 antibody (1/20;
SC7846, SantaCruz Biotechnology Inc). The next day, immunofluorescent
labelling was visualized by using a rabbit anti-goat secondary antibody,
conjugated to Alexa Fluor-488 (1/200). Inflammation was analysed by a
CD45 staining and a CD31 staining was performed to check the blood
vessels. The mice samples were incubated overnight with rat antimouse
CD45 antibody (1/100; 553076; Pharmingen, Erembodegem, Belgium) or
rat antimouse CD31 (1/500; 557355; Pharmingen), respectively. The
following day, the bound antibodies were visualized by using the Perkin
Elmer kit (Renaissance TSATM Indirect; NEL704A; Waltham, MA, USA)
and with cyanin 3 as fluorophore. Deposition of collagen was analysed in
both groups by Sirius Red staining.
Imaging and analysis
Images were obtained by using a microscope (Leica Microsystems,
Wetzlar, Germany), equipped with a digital camera (Axiocam MrC5; Carl
Zeiss), at a magnification of 209 and a resolution of 2584 9 1936 pix-
els. Morphometric analyses were performed with commercial software
(KS300; Zeiss). As described above, the bleb was localized on the first
slide of each series, based on the haematoxylin and eosin staining. The
consecutive slides, on which the bleb was located, were used to per-
form the different (immuno)histological stainings. Analysis of the differ-
ent processes of wound healing was only performed in the bleb (five
sections/eye). The in vivo proliferation was analysed by counting the
number of Ki67-positive cells as a percentage of the total number of
cells with nuclear staining (DAPI) in the bleb [35]. The density of blood
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vessels and leucocytes was determined by calculating, respectively,
the CD31-positive and the CD45-positive area as a proportion of the
bleb area. Deposition of collagen was determined by measuring the
percentage of the collagen positive area in the bleb area under polarized
light.
Statistical analysis
All in vitro and immunomorphometric data were analysed by using the
Student’s t-test for independent samples. Data at individual time-points
were analysed by using mixed model analysis for repeated measures
(with GraphPad Prism 5). Kaplan–Meier survival analysis was performed
for bleb failure by using the log-rank test. P < 0.05 was considered to
be statistically significant. Data are represented as mean  SEM, unless
otherwise stated.
Results
Up-regulation of PlGF in AH of glaucoma
patients and after VEGF-treatment
Glaucoma patients might be predisposed to more aggressive scarring
after filtration surgery because of the presence of different growth
factors in their AH [36]. In previous work, we already showed that
VEGF was significantly up-regulated in AH of glaucoma patients [14].
Aqueous levels of PlGF in glaucoma patients, however, are still
unknown. Therefore, PlGF concentrations in AH samples were analy-
sed by ELISA, and were found to be significantly up-regulated by
40% in glaucoma patients as compared with the controls (n = 10 per
group, P = 0.03; Fig. 1A). To elucidate whether PlGF in AH originates
from the blood or is locally produced, AH and plasma concentrations
were compared. No significant differences were found in plasma lev-
els of PlGF between patients who underwent trabeculectomy (glau-
coma patients) and cataract patients (control patients) (data not
shown).
We also showed in previous studies that neither selective nor
non-selective VEGF inhibition could reduce inflammation, presumably
because of an up-regulation of PlGF [14, 15]. Therefore, we investi-
gated PlGF levels in AH and plasma of operated rabbits after bev-
acizumab treatment. After surgery, aqueous PlGF was significantly
up-regulated in the control eyes (NaCl injection) from post-operative
day 1 to day 30 as compared with the PlGF levels on the day before
surgery (n = 5; P < 0.05; Fig. 1B). Moreover, bevacizumab was able
to significantly enhance this post-operative PlGF up-regulation (post-
operative days 3 and 7), as compared with the control eyes
[1.30  0.14 fold (P = 0.03) and 1.20  0.03 fold (P = 0.01)
respectively]. PlGF levels were found to be similar in all plasma sam-
ples, taken before or after surgery (data not shown). Plasma of a
pregnant rabbit on day 25 was 18.2  2.44 fold up-regulated com-
pared with normal plasma (P < 0.001; positive control; data not
shown).
The significant increases in PlGF levels in AH, but not in the
plasma, suggest that this growth factor is produced locally and can
importantly contribute to wound healing after glaucoma filtration sur-
gery. Importantly, PlGF was also up-regulated in AH of operated rab-
bits after VEGF inhibition.
Expression of VEGF, PlGF and their receptors by
mouse Tenon fibroblasts
Tenon fibroblasts are regarded as the key players in the initiation of
wound healing and fibrotic scar formation after trabeculectomy. Cells
were isolated from mouse Tenon and after 14 days in culture, they
showed an adherent homogeneous morphology of spindly, generally
flat, elongated shaped cells. Moreover, all cells were found to be im-
munopositive for vimentin and immunonegative for the epithelial cell
marker, cytokeratin. Based on these stainings and their morphology,
the cells were predominantly identified as MTF cultures (Fig. 1C).
Murine melanoma B16/F10 cells, which served as a positive control,
were clearly immunopositive for cytokeratin (data not shown). Quanti-
tative RT-PCR experiments were performed to elucidate the mRNA
expression of VEGF, PlGF and their receptors (VEGF-R1 and – R2).
Although we cannot compare their absolute expression values, our
data do indicate that both growth factors and their receptors are
expressed by MTF (Fig. 1D). Moreover, immunostainings showed
that MTF also expressed both growth factors on protein level. Double
stainings revealed that both VEGF and PlGF colocalized with vimentin
in the cytoplasm of the fibroblast cells (Fig. 1E).
Stimulation of MTF proliferation by VEGF and
PlGF
Growth factors in glaucomatous AH are reported to increase fibro-
blast proliferation by 60% in comparison with AH of controls [36],
which may lead to an increased risk of filtration failure. To determine
the effect of PlGF and VEGF on proliferation of MTF, cells were grown
in serum-free medium to which the growth factors were added. Mur-
ine PlGF, administered at 10, 25, 50 and 100 ng/ml, significantly
increased MTF by 27%, 14%, 21% and 24% respectively (P < 0.05).
Administration of murine VEGF induced a significant increase in MTF
proliferation as compared with serum-free medium, with 27%, 22%,
16% and 18% increase for 10, 25, 50 and 100 ng/ml respectively
(P < 0.05; Fig. 1F).
Overall, these data show that PlGF and VEGF, which are expressed
in AH and by MTF, stimulate MTF proliferation and thus might play an
important role in scar formation after glaucoma filtration surgery.
PlGF and VEGF inhibition reduces MTF
proliferation in vitro
Administration of the anti-PlGF antibody 5D11D4 to MTF did not
result in any inhibitory effects on their cell proliferation, which is not
surprising as PlGF has not been reported to play a major role in physi-
ological processes (P = NS; Fig. 2A). However, when increasing con-
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centrations of the 5D11D4 antibody (0.1, 1, 10 and 100 lg/ml) were
administered together with PlGF (50 ng/ml), PlGF-induced prolifera-
tion of MTF was reduced with 29%, 15%, 31%, 31%, respectively, as
compared with control (0.1% FBS with PlGF; P < 0.05; Fig. 2B). To
investigate the effect of VEGF inhibition on MTF proliferation, we used
the well-described rat antimouse VEGF-R2 antibody DC101 [37, 38],
as a mouse VEGF-specific monoclonal antibody is not available. We
showed that unstimulated MTF proliferation was not affected after
DC101 administration (P = NS; Fig. 2A), whereas VEGF-induced pro-
liferation of MTF was significantly inhibited by DC101 (0.1, 1, 10 and
100 lg/ml) by 31%, 27%, 27% and 29%, respectively, as compared
with control (0.1% FBS with VEGF; P < 0.05; Fig. 2C). An irrelevant
control antibody 1C8 (0.1, 1, 10 and 100 lg/ml) did not influence
(PlGF and VEGF-induced) MTF proliferation (P = NS for all concentra-
tions; Fig. 2A–C). Of note, 5D11D4 did not significantly influence
VEGF-induced cell proliferation, whereas DC101 administration did
not affect PlGF-induced cell growth (P = NS; Fig. 2B and C).
Thus, we demonstrated that administration of neutralizing anti-
bodies to murine PlGF and murine VEGF-R2 reduced, respectively,
PlGF- and VEGF-induced proliferation of MTF, although dose–
response effects were not found.
Optimal route of administration of the anti-PlGF
antibody
Previous study showed intra-ocular safety of anti-PlGF injections in
the eye [28]; however, the most optimal route of administration of the
A C
B D
E
F
Fig. 1 Placental growth factor (PlGF) plays an important role in scar formation in vitro. (A) PlGF levels were up-regulated in aqueous humour of
glaucoma patients (*P = 0.03 versus control participants; n = 10 per group). (B) Bevacizumab treatment induced a significant increase in aqueous
PlGF levels on day 3 (1.3-fold) and 7 (1.2-fold), as compared with control eyes injected with NaCl (*P < 0.05 versus control; n = 5). (C) The cul-
tures of primary murine Tenon fibroblasts (MTF) clearly show an adherent homogeneous morphology of spindly, generally flat, elongated shaped
cells (left panel). The cells are immunopositive for vimentin (red; middle panel), but do not show any staining for the epithelial cell marker, cytokera-
tin (red; right panel). Scale bar: 50 lm. (D) VEGF, PlGF and their receptors (VEGF-R1 and -R2) were expressed by MTF. The mRNA levels were nor-
malized to that of the house keeping gene b-actin. (E) Tenon fibroblasts were immunopositive for vimentin (red; middle panels) and VEGF and PlGF
(green; left panels). VEGF and PlGF both colocalized with vimentin in the cytoplasm of the cells (merge; right panels). 4′,6-diamidino-2-phenylindole
(blue) was used a nuclear counter staining. Scale bar: 50 lm. (F) Addition of recombinant murine VEGF and PlGF (10–100 ng/ml) significantly aug-
mented MTF proliferation [*P < 0.05 versus the control medium, containing 0.1% FBS (white bar)].
1636 ª 2013 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
PlGF antibody is still uncertain. Therefore, surgical outcome after a
single intracameral (AC), subconjunctival (SC) and intravitreal (IV)
injection of the PlGF antibody (5D11D4, 5.2 lg) was compared. Bleb
area and bleb survival were analysed until 14 days after surgery and
showed that the three administration routes of the PlGF antibody were
able to significantly improve bleb area (n = 10; P < 0.001) and bleb
survival (n = 10; P < 0.05) compared with their respective controls
(1C8; 4.8 lg; Fig. 3A). A direct comparison among the three groups
showed no significant difference in bleb area and survival (n = 10;
P = NS; Fig. 3B), suggesting that all injections are able to equally
improve surgical outcome. Based on these results and on the elevated
PlGF levels in the AC of glaucoma patients, intracameral injection was
determined as the most optimal administration route for the following
experiments.
PlGF inhibition improves surgical outcome in a
mouse trabeculectomy model
To further verify whether PlGF inhibition also affects the process of
proliferation and fibrosis in vivo, we investigated the therapeutic
potential of PlGF inhibition (5D11D4) on wound healing in vivo in a
mouse trabeculectomy model. A first group of mice received a single
antibody injection (5.2 lg) in the anterior chamber (AC) immediately
A
B
C
Fig. 2 PlGF and VEGF-R2 inhibition reduces cell growth of MTF in vitro. (A) Administration of 5D11D4, DC101 or 1C8 did not induce any specific
inhibitory effects on basal cell proliferation of MTF (P = NS). (B) 5D11D4 significantly inhibited PlGF-induced proliferation [*P < 0.05 versus 0.1%
FBS + PlGF (black bar)], whereas DC101 and 1C8 did not affect MTF proliferation after PlGF stimulation (P = NS). (C) VEGF-induced proliferation of
MTF was significantly reduced after DC101 administration [*P < 0.05 versus 0.1% FBS + VEGF (black bar)], while 5D11D4 and 1C8 did not have
any effect (P = NS).
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after surgery. To compare the efficacy of 5D11D4 with anti-VEGF
therapy, a second group of mice were injected with an anti-VEGF-R2
antibody (DC101; 6.2 lg AC). IOP was measured in all groups, but
was found to be similar in the treated and control eyes (1C8; 4.8 lg)
at each time-point (P = NS, data not shown). This is not unexpected,
as these mice do not have IOP elevation at baseline. Successful filtra-
tion surgery after antibody administration was evaluated by analysing
bleb area and bleb survival at various time-points after surgery. A sin-
gle injection of the anti-PlGF antibody was able to improve the surgi-
cal outcome until day 14 after surgery (Fig. 4B). Indeed, the bleb area
was significantly larger at each time-point in the treated eyes com-
pared with the eyes injected with the irrelevant antibody, 1C8
(n = 20; P < 0.001). Also bleb survival was prolonged after 5D11D4
treatment, as shown in the Kaplan–Meier survival curve, with 25% of
the blebs surviving in the control group and 70% of the blebs surviv-
ing in the 5D11D4-treated group at 14 days after surgery (n = 20;
P = 0.002). Remarkably, a single injection of the anti-VEGF-R2 anti-
body failed to significantly improve bleb area (n = 20; P = 0.08) and
bleb survival (n = 20; P = 0.06) compared with 1C8 treated eyes,
although a trend was observed (Fig. 4A).
To evaluate microscopically the effects of anti-PlGF antibody on
different phases of wound healing, various (immuno)histological sta-
inings were performed at different time-points after surgery (Fig. 4D).
Of note, in vivo cell proliferation in the bleb area was only checked at
an early time-point (day 8), as it is known that proliferation of differ-
ent cells (such as endothelial cells and fibroblasts) occurs early in the
process of wound healing [4]. Analysis of the different processes of
wound healing was only performed in the bleb (positive area) and
was calculated as a proportion of the total bleb area/total number of
cells. Morphometric quantification of a Ki67 staining revealed a signif-
icant reduction in the number of all proliferating cells after single
5D11D4 or DC101 administration, being 43% and 45%, respectively,
A B
Fig. 3 The most optimal route of administration of the anti-PlGF antibody (A) Bleb area (P < 0.001; n = 10) and bleb survival (P < 0.05; n = 10)
were significantly improved after a single intracameral (AC), subconjunctival (SC) and intravitreal (IV) injection of the PlGF inhibitor, compared with
their respective controls. (B) A direct comparison between the three groups showed no significant difference in bleb area and survival (P = NS;
n = 10).
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as compared with vehicle injected eyes (n = 10; P < 0.05). Eyes trea-
ted with anti-PlGF antibody showed a significant reduction of 50% in
inflammatory area, as compared with 1C8 treated eyes, at 8 days
after surgery (n = 10; P < 0.001). No differences in inflammatory
responses were seen after inhibition of VEGF-R2 (n = 10; P = NS).
On post-operative day 8, blood vessel density was reduced after a
single 5D11D4 or DC101 administration, with 47% and 38%, respec-
tively, compared with control (n = 10; P < 0.001). Inflammation and
angiogenesis were no longer different on post-operative day 14 after
a single administration (n = 10; P = NS). Collagen deposition was
significantly reduced on days 8 and 14 after 5D11D4 administration
by 28% and 21% respectively (n = 10; P = 0.001) and after DC101
injection by 23% and 24% respectively (n = 10; P = 0.003; Fig. 4C).
To distinguish whether the observed difference in efficacy of both
antibodies was caused by a difference in half-life or by a different
working mechanism, repeated intracameral injections of either anti-
body in the same concentrations were given on day 0, 4 and 10. As
expected, repeated administration of 5D11D4 was able to significantly
improve the bleb area up until 14 days (n = 10; P < 0.001) and to
prolong bleb survival after filtration surgery compared with 1C8, as
A
C
D
B
Fig. 4 Single intracameral injection of anti-PlGF antibody improves surgical outcome in a mouse trabeculectomy model. (A) Bleb area was signifi-
cantly larger at each time-point compared with control after administration of the anti-PlGF antibody (P < 0.001; n = 20), whereas anti-VEGF-R2
antibody did not significantly improve bleb area (P = NS; n = 20). 5D11D4 also significantly prolonged bleb survival (P = 0.002; n = 20), while
DC101 did not (P = NS; n = 20). (B) It shows macroscopic post-operative photographs of the blebs on days 1 and 7 after surgery. Arrows: edges
of the blebs. (C) Treatment of 5D11D4 significantly decreased the process of inflammation at the filtration site on day 8, whereas DC101 did not.
Proliferation, blood vessel density and collagen deposition were reduced after single administration of anti-PlGF and anti-VEGF-R2 antibody
(*P < 0.05 compared to 1C8; n = 10 per time point). (D) The images show representative pictures of immunostainings of eyes treated with
5D11D4 (upper panels) or with DC101 (middle panels) or control eyes (lower panels), at 8 days after surgery. Edges of the blebs are marked by a
dotted line and were indicated as the positive area of analysis (+), whereas the rest of the eye was indicated as the negative area of analysis ().
Scale bar: 50 lm.
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shown in the Kaplan–Meier survival curve (n = 10; P = 0.006).
Repeated injections of DC101 were also able to significantly improve
surgical outcome. Indeed, the bleb area was significantly enlarged at
each time-point in the treated eyes compared with the control eyes
(n = 10; P = 0.005) and bleb survival was significantly prolonged
(n = 10; P = 0.02; Fig. 5A and B). Mice were killed 14 days after sur-
gery and quantification of immunohistochemical stainings showed no
effect on inflammation and angiogenesis in the eyes treated with
5D11D4 or DC101 in comparison with control eyes (n = 10;
P = NS). Fibrosis on post-operative day 14, however, was signifi-
cantly decreased after repeated antibody administration by 41% and
48%, respectively, compared with control (n = 10; P < 0.001;
Fig. 5C).
Thus, administration of an anti-PlGF antibody could improve the
outcome in filtration surgery by reducing post-operative inflammation
and angiogenesis during the first post-operative days after surgery,
and by affecting collagen deposition at later stages. Furthermore, inhi-
bition of PlGF seems to be more effective than anti-VEGF-R2 treat-
ment in improving surgical outcome through its additional effect on
inflammation. Indeed, direct comparison between the two antibodies
showed that single (n = 20; P = 0.02) and repeated (n = 10;
P = 0.005) administration of 5D11D4 significantly improved bleb
area, whereas DC101 administration only resulted in a small effect on
bleb area until post-operative day 14 (data not shown). No significant
differences were seen in bleb survival (P = NS; data not shown).
Discussion
In previous studies, we have shown that neither selective nor non-
selective VEGF inhibition can reduce the inflammatory response in a
rabbit trabeculectomy model [14, 15], possibly because of an up-reg-
ulation of another VEGF family member, PlGF [20–22]. Here, we now
revealed that aqueous PlGF levels were indeed significantly increased
at different time-points after glaucoma surgery in this rabbit model.
This can be explained by the release of PlGF by Tenon fibroblasts and
possibly other cells, such as endothelial and inflammatory cells.
These cells are also important in the post-operative process of wound
healing and are known to express PlGF [24, 25]. Moreover, bev-
acizumab treatment was able to enhance this post-operative PlGF up-
regulation within the first week after glaucoma surgery. It is known
from previous studies that inflammation peaks within the initial days
post-surgery in eyes treated with bevacizumab [14]. Therefore, we
hypothesize that the up-regulated levels of aqueous PlGF after bev-
acizumab administration might form an explanation why anti-VEGF-
therapy was not sufficient to reduce the inflammatory response in our
trabeculectomy model [14, 15]. To further investigate whether PlGF
inhibition might influence the post-operative wound healing process
through its known anti-angiogenic, anti-inflammatory and possibly
anti-fibrotic properties, we used a previously characterized monoclo-
nal antibody (clone 5D11D4) against murine PlGF, produced at
ThromboGenics NV. As the available neutralizing antibodies to PlGF
A
C
B
Fig. 5 Repeated injections of anti-PlGF antibody improves surgical outcome in a mouse trabeculectomy model. (A) Repeated injections of the anti-
PlGF antibody and anti-VEGF-R2 antibody significantly enlarged bleb area (P < 0.001 and P = 0.005, respectively; n = 10) and survival (P = 0.006
and P = 0.02, respectively; n = 10) compared with control. (B) It shows macroscopic post-operative photographs of the blebs on days 1 and 7 after
surgery. Arrows: edges of the blebs. (C) Repeated injections of the antibodies did not affect inflammation and angiogenesis. The process of collagen
deposition was significantly reduced on post-operative day 14, after repeated 5D11D4 and DC101 administration compared with control (*P < 0.05
compared to 1C8; n = 10).
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did not cross-react with rabbit PlGF (data not shown), a recently
developed mouse model for filtration surgery was set up [32, 33] to
mimic wound healing after glaucoma surgery.
Placental growth factor is a pleiotropic molecule and is known to
stimulate endothelial cell growth and migration [24] and the process
of fibrosis [39]. Although the anti-proliferative effect on endothelial
cells by anti-PlGF antibody is well described [26], the effect on Tenon
fibroblasts is still unknown. We showed that administration of anti-
PlGF (5D11D4) and anti-VEGF-R2 (DC101) to primary cultures of
MTF significantly reduced cell number, whereas the irrelevant anti-
body (1C8) did not induce any differences in cell proliferation.
Remarkably, no dose–response effects of the antibodies on PlGF- and
VEGF-induced cell proliferation were seen. This can possibly be
explained by the secretion and autocrine regulation of PlGF and VEGF
by these cells, as described in literature [40–42]. We indeed showed
that exogenous growth factors only modestly increased the growth of
Tenon fibroblasts. These results are in line with those reported by
Cianfarani et al., who also observed a modest increase in dermal
fibroblast proliferation at 48 hrs after PlGF administration, without a
dose–response effect [39]. We also revealed that MTF are producing
VEGF and PlGF, which can bind to the VEGF receptors, known to be
expressed on these cells. Moreover, both growth factors are reported
to be expressed at relatively high level by fibroblasts [14, 43]. There-
fore, we believe that adding exogenous PlGF and VEGF to fibroblasts
may have a relatively limited effect on proliferation because of this
endogenous production, which possibly explains the absence of a
dose–response effect.
The mouse model of glaucoma surgery was used to confirm the
anti-proliferative and anti-fibrotic properties of the anti-PlGF antibody
in vivo. In this mouse model, the most common reason for bleb fail-
ure is scarring and fibrosis [32]; therefore, bleb area and survival
were investigated as an indication for the fibrotic wound healing
response. The intracameral administration route of the PlGF antibody
was chosen rather than the subconjunctival and intravitreal route.
Although we showed that the three ways of injection of the PlGF
inhibitor were able to equally improve surgical outcome, the rationale
of this approach is the fact that we found elevated intracameral levels
of PlGF in glaucoma patients. This suggests a role of intracameral
PlGF in the wound healing process. Anti-PlGF treatment at the time of
surgery should therefore aim at preventing PlGF binding to its recep-
tors, but also at preventing PlGF release into AH. An intracameral
delivery of the PlGF inhibitor allows blocking this aqueous PlGF. Fur-
thermore, the injected anti-PlGF subsequently passes through the
constructed channel, under the flap and into the bleb, where it can
also prevent receptor-binding and exert its anti-angiogenic and anti-
fibrotic actions. Moreover, subconjunctival injections have the disad-
vantage of disturbing and stretching the blebs, which may stimulate
inflammation and fibroblast activation. Finally, there are also advanta-
ges of an intracameral injection over an intravitreal injection. The for-
mer can be easily performed with a blunt cannula through the
paracentesis already available. Complications associated with intravi-
treal injections, such as retinal detachment, are thus avoided [44].
We showed that a single intracameral injection of anti-PlGF was
effective in improving the surgical outcome, by increasing bleb area
and survival until 14 days after surgery, compared with irrelevant
antibody 1C8. The pleiotrophic working mechanisms of the anti-PlGF
antibody were revealed by immunohistochemistry and analysis
showed that overall cell proliferation and angiogenesis was reduced
during the initial days of healing and fibrosis at later stages. Impor-
tantly, besides affecting proliferation, angiogenesis and fibrosis, the
anti-PlGF antibody also had an anti-inflammatory effect in the process
of wound healing. PlGF has indeed been described as a chemo-attrac-
tant for pro-angiogenic inflammatory cells via its binding to VEGF-R1
[25]. Anti-PlGF attenuates the tissue infiltration by blood-borne mac-
rophages and thereby importantly contributes to angiogenesis by
secreting angiogenic factors [45]. Moreover, an increase in macro-
phages also leads to enhanced scar formation in tumour models [26].
Remarkably, single administration of 5D11D4 showed to be more
potent than the anti-VEGF-R2 antibody in improving bleb area. To elu-
cidate whether the observed difference in efficacy was caused by a
difference in half-life or by a different working mechanism of both
antibodies, repeated injections on days 0, 4 and 10 were given.
Indeed, the systemic half-life of DC101 (4.21 days) was significantly
shorter than that of 5D11D4 (7.75 days) [26], which suggests identi-
cal properties for the intraocular half-life. Repeated injections revealed
that both antibodies were able to improve surgical outcome. Anti-PlGF
administration seemed even more effective than inhibition of VEGF-
R2. Indeed, a direct comparison of the clinical outcome showed
significant differences in bleb area. In contrast to anti-PlGF therapy,
anti-VEGF-R2 was able to reduce neovascularization and fibrosis
during the wound healing process, but it failed to inhibit infiltration of
inflammatory cells. This is consistent with the fact that inflammatory
cells do not express VEGF-R2 [46], whereas endothelial cells [47] and
Tenon fibroblasts do [14]. Therefore, we hypothesize that the differ-
ence in efficacy of both antibodies could be explained by a different
working mechanism, rather than their difference in half-life. Impor-
tantly, our results are in keeping with previous studies that showed
that anti-PlGF antibody (5D11D4) could reduce angiogenesis and
inflammation in preclinical tumour [26] and age-related macular
degeneration models [28], whereas inhibition of VEGF-R2 only had an
effect on neovascularization. So, administration of anti-PlGF antibody
can improve the surgical outcome by reducing the post-operative pro-
cesses of wound healing, and might be possibly more effective than
inhibition of VEGF, because of its additional effect on inflammation.
Although we showed that anti-PlGF treatment was effective in tar-
geting different phases in the process of wound healing, it remains
necessary to broaden the therapeutic approach for filtration failure.
Treatment with a single anti-angiogenic agent may indeed lead to
drug resistance, because of up-regulation of other growth factors.
This is based on escape mechanisms via induction of an angiogenic
rescue programme. It is known that PlGF levels are increased up to
10-fold in various tumour models after VEGF inhibition [20–22].
Therefore, a combination of anti-VEGF and anti-PlGF would be a pos-
sible option to reduce the escape mechanism and to affect the three
most important wound healing phases: inflammation, angiogenesis
and collagen deposition. Although it was initially thought that the
post-embryonic role of VEGF was restricted to a few processes for
which angiogenesis is critical, such as the female reproductive cycle
[13], it is becoming obvious that VEGF acts as a pleiotrophic growth
factor essential for different physiological processes, such as mainte-
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nance of the adult vasculature in many organs [48–50] and neuronal
survival [51]. As such, because of its essential role in blood vessel
formation and maintenance and in neuronal survival, inhibiting VEGF
with antibodies at high doses might create severe side effects. PlGF,
on the other hand, is an important player in angiogenesis, but only in
pathological processes like cancer and inflammation, rather than
physiological angiogenesis. Therefore, blocking PlGF with an antibody
does not affect the normal vasculature. Furthermore, anti-PlGF was
previously reported to enhance the efficacy of VEGF inhibitors [26].
Therefore, combination of the optimal dose of anti-PlGF with a subop-
timal dose of anti-VEGF (which does not induce any side effects)
would probably lead to additional inhibition of scar formation com-
pared with monotherapy of either. Of note, it has been suggested that
a lower dose of anti-VEGF might sensitize the vessels for anti-PlGF.
Indeed, a study of Van de Veire et al. in a mouse model of CNV
showed that addition of anti-PlGF allowed a fourfold reduction in the
anti-VEGF dose without losing its efficacy [28]. Further comparative
studies will be necessary to investigate whether this is also true in fil-
tration surgery. The pleiotrophic and complementary mechanisms of
anti-PlGF suggest that anti-PlGF may be useful as adjunctive to VEGF
inhibition. As such, combining these therapeutic agents may allow
reducing their doses, while improving the safety profile of the anti-
scarring treatment.
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